Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Sep
07
Today In Oncology
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo